Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration

Nature Medicine

Volumn 18, Issue 6, 2012, Pages 934-942

  Sun, Zheng ^a,b   Miller, Russell A ^a,b   Patel, Rajesh T ^a,b   Chen, Jie ^c   Dhir, Ravindra ^a,b   Wang, Hong ^d   Zhang, Dongyan ^e   Graham, Mark J ^f   Unterman, Terry G ^g,h   Shulman, Gerald I ^e   Sztalryd, Carole ^d   Bennett, Michael J ^a,c   Ahima, Rexford S ^a,b   Birnbaum, Morris J ^a,b   Lazar, Mitchell A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ISIS PHARMACEUTICALS   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^h Jesse Brown Virginia Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAT DROPLET; HISTONE DEACETYLASE 3; PERILIPIN; PERILIPIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CIRCADIAN RHYTHM; CONTROLLED STUDY; ENZYME SPECIFICITY; FATTY LIVER; GLUCONEOGENESIS; INHIBITION KINETICS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIPOGENESIS; LIVER METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; DIET, HIGH-FAT; FATTY LIVER; GLUCONEOGENESIS; GLUCOSE; HISTONE DEACETYLASES; INSULIN; INSULIN RESISTANCE; LIPIDS; LIVER; MALE; MICE; MICE, INBRED C57BL;

MUS;

EID: 84862025421     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2744     Document Type: Article

References (60)

1. Cohen, J.C., Horton, J.D. & Hobbs, H.H. Human fatty liver disease: old questions and new insights. Science 332, 1519-1523 (2011).
2. Browning, J.D. & Horton, J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114, 147-152 (2004). (Pubitemid 39071617)
3. Utzschneider, K.M. & Kahn, S.E. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 91, 4753-4761 (2006). (Pubitemid 44917301)
4. Nagle, C.A., Klett, E.L. & Coleman, R.A. Hepatic triacylglycerol accumulation and insulin resistance. J. Lipid Res. 50 (suppl.), S74-S79 (2009).
5. Postic, C. & Girard, J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J. Clin. Invest. 118, 829-838 (2008). (Pubitemid 351364588)
6. Samuel, V.T., Petersen, K.F. & Shulman, G.I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375, 2267-2277 (2010).
7. Lonardo, A., Bellentani, S., Ratziu, V. & Loria, P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient-death of a dogma from analysis of therapeutic studies? Expert Rev. Gastroenterol. Hepatol. 5, 279-289 (2011).
8. Lass, A., Zimmermann, R., Oberer, M. & Zechner, R. Lipolysis-a highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores. Prog. Lipid Res. 50, 14-27 (2011).
9. Donnelly, K.L. et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115, 1343-1351 (2005). (Pubitemid 40629054)
10. Larter, C.Z. & Yeh, M.M. Animal models of NASH: getting both pathology and metabolic context right. J. Gastroenterol. Hepatol. 23, 1635-1648 (2008).
11. Biddinger, S.B. & Kahn, C.R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 68, 123-158 (2006).
12. Taniguchi, C.M. et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCa;/ζ. Cell Metab. 3, 343-353 (2006).
13. Leavens, K.F., Easton, R.M., Shulman, G.I., Previs, S.F. & Birnbaum, M.J. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab. 10, 405-418 (2009).
14. Brown, M.S. & Goldstein, J.L. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 7, 95-96 (2008). (Pubitemid 351168559)
15. Stiles, B. et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity. Proc. Natl. Acad. Sci. USA 101, 2082-2087 (2004). (Pubitemid 38229018)
16. Greenberg, A.S. et al. The role of lipid droplets in metabolic disease in rodents and humans. J. Clin. Invest. 121, 2102-2110 (2011).
17. Matsuzaka, T. et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat. Med. 13, 1193-1202 (2007). (Pubitemid 47530641)
18. Brown, J.M. et al. CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance. J. Lipid Res. 51, 3306-3315 (2010).
19. Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343-1350 (2001). (Pubitemid 32378388)
20. Bass, J. & Takahashi, J.S. Circadian integration of metabolism and energetics. Science 330, 1349-1354 (2010).
21. Desvergne, B., Michalik, L. & Wahli, W. Transcriptional regulation of metabolism. Physiol. Rev. 86, 465-514 (2006).
22. Feng, D. et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 331, 1315-1319 (2011).
23. Panda, S. et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 109, 307-320 (2002). (Pubitemid 34606874)
24. Lawless, M.W., Norris, S., O'Byrne, K.J. & Gray, S.G. Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disorders. Endocr. Metab. Immune Disord. Drug Targets 9, 84-107 (2009).
25. Sun, Z., Feng, D., Everett, L.J., Bugge, A. & Lazar, M.A. Circadian epigenomic remodeling and hepatic lipogenesis: lessons from HDAC3. Cold Spring Harb. Symp. Quant. Biol. published online, doi:10.1101/sqb.2011.76.011494 (6 September 2011).
26. Knutson, S.K. et al. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J. 27, 1017-1028 (2008). (Pubitemid 351508160)
27. Mullican, S.E. et al. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev. 25, 2480-2488 (2011).
28. Bell, P. et al. Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs. Hum. Gene Ther. 22, 985-997 (2011).
29. Samuel, V.T. et al. Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J. Clin. Invest. 117, 739-745 (2007). (Pubitemid 46348532)
30. Calvo, M.N. et al. PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay and inhibits anchorage-independent growth in HeLa cells. FEBS Lett. 580, 3308-3314 (2006). (Pubitemid 44251000)
31. Bolaños, J.P., Almeida, A. & Moncada, S. Glycolysis: a bioenergetic or a survival pathway? Trends Biochem. Sci. 35, 145-149 (2010).
32. Seo, Y.-K. et al. Genome-wide analysis of SREBP-1 binding in mouse liver chromatin reveals a preference for promoter proximal binding to a new motif. Proc. Natl. Acad. Sci. USA 106, 13765-13769 (2009).
33. Seo, Y.-K. et al. Genome-wide localization of SREBP-2 in hepatic chromatin predicts a role in autophagy. Cell Metab. 13, 367-375 (2011).
34. Wendel, A.A., Lewin, T.M. & Coleman, R.A. Glycerol-3-phosphate acyltransferases: rate limiting enzymes of triacylglycerol biosynthesis. Biochim. Biophys. Acta 1791, 501-506 (2009).
35. Brasaemle, D.L. Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. J. Lipid Res. 48, 2547-2559 (2007). (Pubitemid 350272839)
36. Gong, J., Sun, Z. & Li, P. CIDE proteins and metabolic disorders. Curr. Opin. Lipidol. 20, 121-126 (2009).
37. Puri, V. et al. Fat-specific protein 27, a novel lipid droplet protein that enhances triglyceride storage. J. Biol. Chem. 282, 34213-34218 (2007). (Pubitemid 350159455)
38. Samuel, V.T. et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279, 32345-32353 (2004). (Pubitemid 39014687)
39. Hammond, L.E. et al. Mitochondrial glycerol-3-phosphate acyltransferase-1 is essential in liver for the metabolism of excess acyl-CoAs. J. Biol. Chem. 280, 25629-25636 (2005). (Pubitemid 40962271)
40. Nilsson, A., Thomassen, M.S. & Christiansen, E. Long-chain Acyl-CoA levels in liver from rats fed high-fat diets: is it of significance for an increased peroxisomal β-oxidation? Lipids 19, 187-194 (1984). (Pubitemid 14145343)
41. Mihaylova, M.M. et al. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 145, 607-621 (2011).
42. Chang, B.H.-J. et al. Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein. Mol. Cell. Biol. 26, 1063-1076 (2006). (Pubitemid 43146498)
43. Imai, Y. et al. Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide. Gastroenterology 132, 1947-1954 (2007). (Pubitemid 46677941)
44. Mutel, E. et al. Control of blood glucose in the absence of hepatic glucose production during prolonged fasting in mice: induction of renal and intestinal gluconeogenesis by glucagon. Diabetes 60, 3121-3131 (2011).
45. Vogt, P.K., Jiang, H. & Aoki, M. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 4, 908-913 (2005). (Pubitemid 41359756)
46. Zhang, W. et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J. Biol. Chem. 281, 10105-10117 (2006). (Pubitemid 43864546)
47. Banks, A.S. et al. Dissociation of the glucose and lipid regulatory functions of FoxO1 by targeted knockin of acetylation-defective alleles in mice. Cell Metab. 14, 587-597 (2011).
48. Haeusler, R.A., Han, S. & Accili, D. Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia. J. Biol. Chem. 285, 26861-26868 (2010).
49. Tao, R. et al. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J. Biol. Chem. 286, 14681-14690 (2011).
50. Kadereit, B. et al. Evolutionarily conserved gene family important for fat storage. Proc. Natl. Acad. Sci. USA 105, 94-99 (2008).
51. Yang, X. et al. The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab. 11, 194-205 (2010).
52. Bell, M. et al. Consequences of lipid droplet coat protein downregulation in liver cells: abnormal lipid droplet metabolism and induction of insulin resistance. Diabetes 57, 2037-2045 (2008).
53. Kantartzis, K. et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58, 2616-2623 (2009).
54. Minehira, K. et al. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J. Lipid Res. 49, 2038-2044 (2008).
55. Schonfeld, G., Yue, P., Lin, X. & Chen, Z. Fatty liver and insulin resistance: not always linked. Trans. Am. Clin. Climatol. Assoc. 119, 217-223, discussion 223-224 (2008).
56. Chang, B.H.-J., Li, L., Saha, P. & Chan, L. Absence of adipose differentiation related protein upregulates hepatic VLDL secretion, relieves hepatosteatosis, and improves whole body insulin resistance in leptin-deficient mice. J. Lipid Res. 51, 2132-2142 (2010).
57. Gerstein, H.C. et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008). (Pubitemid 351831356)
58. Sapiro, J.M., Mashek, M.T., Greenberg, A.S. & Mashek, D.G. Hepatic triacylglycerol hydrolysis regulates peroxisome proliferator-activated receptor α activity. J. Lipid Res. 50, 1621-1629 (2009).
59. Kumashiro, N. et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl. Acad. Sci. USA 108, 16381-16385 (2011).
60. Sztalryd, C. et al. Functional compensation for adipose differentiation-related protein (ADFP) by Tip47 in an ADFP null embryonic cell line. J. Biol. Chem. 281, 34341-34348 (2006). (Pubitemid 46043256)